Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Onychomycosis

INTRODUCTION

Onychomycosis refers to nail infections caused by any fungus, including yeasts and nondermatophyte molds. Dermatophytic onychomycosis (tinea unguium) occurs in three main forms: distal subungual, proximal subungual, and white superficial. One or several of the toenails or fingernails may be involved, seldom all. Most affected individuals have or have had tinea pedis as well. Most toenail onychomycosis is due to dermatophytes; however, many cases of fingernail onychomycosis are due to yeast.

This topic will review the diagnosis and management of onychomycosis. Skin infections due to dermatophytes and yeast are discussed separately. (See "Dermatophyte (tinea) infections" and "Candidal intertrigo".)

EPIDEMIOLOGY AND MICROBIOLOGY

There are few large community-based studies looking at the epidemiology of onychomycosis. A study of 15,000 patients in Canada presenting to the offices of three dermatologists and one family clinician found that 8 percent had onychomycosis [1]. Most patients had only toenail involvement (7.6 percent); few had fingernail involvement alone (0.15 percent) or both toenail and fingernail involvement (0.27 percent).

In small studies, the prevalence of onychomycosis varies from 4 to 18 percent depending upon the age and population studied [2,3].

Toenail onychomycosis is most commonly due to dermatophytes [1,4,5]; fingernail onychomycosis is more likely than toenail onychomycosis to be due to yeast [1], and some studies have found that yeast are the most common cause of fingernail onychomycosis [4,5]. Nondermatophyte molds appear to cause less than 10 percent of toenail onychomycosis and to be a very rare cause of fingernail onychomycosis [1].

                                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Aug 6, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. J Am Acad Dermatol 2000; 43:244.
  2. Erbagci Z, Tuncel A, Zer Y, Balci I. A prospective epidemiologic survey on the prevalence of onychomycosis and dermatophytosis in male boarding school residents. Mycopathologia 2005; 159:347.
  3. Sahin I, Kaya D, Parlak AH, et al. Dermatophytoses in forestry workers and farmers. Mycoses 2005; 48:260.
  4. Romano C, Gianni C, Difonzo EM. Retrospective study of onychomycosis in Italy: 1985-2000. Mycoses 2005; 48:42.
  5. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol 2004; 50:748.
  6. Ploysangam T, Lucky AW. Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. J Am Acad Dermatol 1997; 36:29.
  7. Sigurgeirsson B, Steingrímsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol 2004; 18:48.
  8. Piérard GE, Piérard-Franchimont C. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses 2005; 48:339.
  9. Muñoz-Pérez MA, Rodriguez-Pichardo A, Camacho F, Colmenero MA. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br J Dermatol 1998; 139:33.
  10. Zaias N, Tosti A, Rebell G, et al. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996; 34:302.
  11. Faergemann J, Correia O, Nowicki R, Ro BI. Genetic predisposition--understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venereol 2005; 19 Suppl 1:17.
  12. Lubeck DP, Gause D, Schein JR, et al. A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res 1999; 8:121.
  13. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36:754.
  14. Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999; 41:189.
  15. Roujeau JC, Sigurgeirsson B, Korting HC, et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004; 209:301.
  16. Bristow IR, Spruce MC. Fungal foot infection, cellulitis and diabetes: a review. Diabet Med 2009; 26:548.
  17. Hay RJ, Baran R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol 2011; 65:1219.
  18. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol 2008; 128:2640.
  19. Finch J, Arenas R, Baran R. Fungal melanonychia. J Am Acad Dermatol 2012; 66:830.
  20. Shemer A, Davidovici B, Grunwald MH, et al. New criteria for the laboratory diagnosis of nondermatophyte moulds in onychomycosis. Br J Dermatol 2009; 160:37.
  21. Gupta AK. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Podiatr Med Assoc 2002; 92:272.
  22. Elewski BE, Leyden J, Rinaldi MG, Atillasoy E. Office practice-based confirmation of onychomycosis: a US nationwide prospective survey. Arch Intern Med 2002; 162:2133.
  23. Lawry MA, Haneke E, Strobeck K, et al. Methods for diagnosing onychomycosis: a comparative study and review of the literature. Arch Dermatol 2000; 136:1112.
  24. Lilly KK, Koshnick RL, Grill JP, et al. Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. J Am Acad Dermatol 2006; 55:620.
  25. Wilsmann-Theis D, Sareika F, Bieber T, et al. New reasons for histopathological nail-clipping examination in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol 2011; 25:235.
  26. Weinberg JM, Koestenblatt EK, Tutrone WD, et al. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol 2003; 49:193.
  27. Lim CS, Lim SL. New contrast stain for the rapid diagnosis of onychomycosis. Arch Dermatol 2011; 147:981.
  28. Litz CE, Cavagnolo RZ. Polymerase chain reaction in the diagnosis of onychomycosis: a large, single-institute study. Br J Dermatol 2010; 163:511.
  29. Tsunemi Y, Takehara K, Miura Y, et al. Screening for tinea unguium by Dermatophyte Test Strip. Br J Dermatol 2014; 170:328.
  30. Crawford F. Athlete's foot and fungally infected toe nails. Clin Evid 2002; :1458.
  31. Arenas R, Fernández G, Domínguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991; 30:586.
  32. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32:750.
  33. Hofmann H, Bräutigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol 1995; 131:919.
  34. Scher RK. Onychomycosis: therapeutic update. J Am Acad Dermatol 1999; 40:S21.
  35. Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38:S77.
  36. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Pharmacoeconomics 1998; 13:243.
  37. Havu V, Heikkilä H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000; 142:97.
  38. Salo H, Pekurinen M. Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. Pharmacoeconomics 2002; 20:319.
  39. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150:537.
  40. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999; 318:1031.
  41. Kejda J. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgrad Med 1999; Spec No:12.
  42. Degreef H, del Palacio A, Mygind S, et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol 1999; 79:221.
  43. De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 1999; 141 Suppl 56:15.
  44. Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010; 62:411.
  45. Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002; 138:811.
  46. Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138:353.
  47. Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2005; 53:578.
  48. Warshaw EM, Bowman T, Bodman MA, et al. Satisfaction with onychomycosis treatment. Pulse versus continuous dosing. J Am Podiatr Med Assoc 2003; 93:373.
  49. Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2012; 166:389.
  50. Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997; 36:395.
  51. Chang CH, Young-Xu Y, Kurth T, et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med 2007; 120:791.
  52. Sigurgeirsson B, van Rossem K, Malahias S, Raterink K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol 2013; 69:416.
  53. Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002; 236:1.
  54. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43:S57.
  55. de Berker D. Clinical practice. Fungal nail disease. N Engl J Med 2009; 360:2108.
  56. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008; 166:353.
  57. Ciclopirox (Penlac) nail lacquer for onychomycosis. Med Lett Drugs Ther 2000; 42:51.
  58. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43:S70.
  59. Friedlander SF, Chan YC, Chan YH, Eichenfield LF. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy. Pediatr Dermatol 2013; 30:316.
  60. Gupta AK, Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005; 4:481.
  61. Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat 2005; 16:327.
  62. Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol 2010; 28:151.
  63. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17 Suppl 1:41.
  64. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992; 17 Suppl 1:44.
  65. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19:21.
  66. Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007; 157:149.
  67. Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2010; 162:46.
  68. Amichai B, Mosckovitz R, Trau H, et al. Iontophoretic terbinafine HCL 1.0% delivery across porcine and human nails. Mycopathologia 2010; 169:343.
  69. Nair AB, Kim HD, Chakraborty B, et al. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 2009; 98:4130.
  70. Derby R, Rohal P, Jackson C, et al. Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series. J Am Board Fam Med 2011; 24:69.
  71. Ramsewak RS, Nair MG, Stommel M, Selanders L. In vitro antagonistic activity of monoterpenes and their mixtures against 'toe nail fungus' pathogens. Phytother Res 2003; 17:376.
  72. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013; 68:600.
  73. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl.pdf (Accessed on July 09, 2014).
  74. Ortiz AE, Avram MM, Wanner MA. A review of lasers and light for the treatment of onychomycosis. Lasers Surg Med 2014; 46:117.
  75. Ledon JA, Savas J, Franca K, et al. Laser and light therapy for onychomycosis: a systematic review. Lasers Med Sci 2014; 29:823.
  76. Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol 2013; 69:578.
  77. Kimura U, Takeuchi K, Kinoshita A, et al. Treating onychomycoses of the toenail: clinical efficacy of the sub-millisecond 1,064 nm Nd: YAG laser using a 5 mm spot diameter. J Drugs Dermatol 2012; 11:496.
  78. Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther 2011; 13:2.
  79. Noguchi H, Miyata K, Sugita T, et al. Treatment of onychomycosis using a 1064nm Nd:YAG laser. Med Mycol J 2013; 54:333.
  80. Waibel J, Wulkan AJ, Rudnick A. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J Drugs Dermatol 2013; 12:1237.
  81. Zhang RN, Wang DK, Zhuo FL, et al. Long-pulse Nd:YAG 1064-nm laser treatment for onychomycosis. Chin Med J (Engl) 2012; 125:3288.
  82. Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc 2010; 100:166.
  83. Hollmig ST, Rahman Z, Henderson MT, et al. Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol 2014; 70:911.
  84. Gupta A, Simpson F. Device-based therapies for onychomycosis treatment. Skin Therapy Lett 2012; 17:4.
  85. Lim EH, Kim HR, Park YO, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol 2014; 70:918.
  86. Watanabe D, Kawamura C, Masuda Y, et al. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008; 144:19.
  87. Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008; 59:S75.
  88. Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial. Acta Derm Venereol 2010; 90:216.
  89. Gilaberte Y, Aspiroz C, Martes MP, et al. Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J Am Acad Dermatol 2011; 65:669.
  90. Gupta AK, Gregurek-Novak T, Konnikov N, et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. J Cutan Med Surg 2001; 5:206.
  91. De Doncker PR, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36:173.
  92. Lebwohl MG, Daniel CR, Leyden J, et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 2001; 40:358.
  93. Warshaw EM, Nelson D, Carver SM, et al. A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis. Int J Dermatol 2005; 44:785.
  94. Rigopoulos D, Katoulis AC, Ioannides D, et al. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 2003; 149:151.
  95. Gupta AK, De Doncker P, Haneke E. Itraconazole pulse therapy for the treatment of Candida onychomycosis. J Eur Acad Dermatol Venereol 2001; 15:112.
  96. Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35:958.
  97. Montgomery BJ. Urea plasters alternative to surgery for nail removal. JAMA 1979; 241:1559, 1563.
  98. Averill RW, Scher RK. Simplified nail taping with urea ointment for nonsurgical nail avulsion. Cutis 1986; 38:231.
  99. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37:740.
  100. Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998; 197:162.
  101. Warshaw EM, St Clair KR. Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. J Am Acad Dermatol 2005; 53:717.